ArticleJBMR plus2026
Establishment and characterization of a human pre-osteocyte cell line: hOsteo4-E9.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteocytes, as the most abundant and long-lived cell type in bone tissue, have garnered significant attention due to their critical roles in bone remodeling, bone mechanobiology, bone-related diseases, and systemic homeostasis. While several well-established murine osteocyte cell lines are available, the development of a reliable human-derived osteocyte cell line remains an unmet need in the field. Here, we report the successful purification of primary bone cells from the adult human lumbar articular process and their immortalization via SV40 antigen transduction. The resulting human cell line, designated hOsteo4, exhibits high expression of early osteocyte markers (E11, DMP1), moderate levels of ALP and COL1, and low expression of late osteocyte markers (sclerostin, FGF23). Quantitative PCR analysis and in vitro osteoblastic differentiation assays indicate that hOsteo4 cells represent pre-osteocytes at the transitional stage from late osteoblasts to osteocytes. Notably, the subclone hOsteo4-E9 demonstrates robust responsiveness to fluid shear stress (FSS), characterized by dramatic morphological remodeling and upregulated focal adhesion protein expression. RNA-sequencing further reveals distinct FSS-responsive gene expression profiles when comparing human hOsteo4-E9 to the murine MLO-Y4 cell line. Collectively, hOsteo4-E9, a novel immortalized human pre-osteocyte-like cell line, represents an invaluable experimental tool that promises to advance mechanistic insights into human osteocyte biology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.